Patents Assigned to Agendia B.V.
  • Prognostic gene expression signature for non small cell lung cancer patients
    Patent number: 8969000
    Abstract: The invention relates to a method of typing non-small cell lung cancer by determining RNA levels for a set of genes. The typing can be used for determining a metastasizing potential of the cancer cells. The invention further relates to a set of probes and a set of primers for typing non-small cell cancer cells.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: March 3, 2015
    Assignee: Agendia B.V.
    Inventors: Paul Roepman, Nico Van Zandwijk, Annuska Maria Glas
  • Methods and means for typing a sample comprising colorectal cancer cells
    Patent number: 8921051
    Abstract: The invention relates to a method of typing colorectal cancer cells by determining the RNA levels of a set of signature genes. Said typing can be use for predicting a risk for recurrence of said colorectal cancer. The invention further relates to a set of genes that can be used for normalizing the RNA levels of said set of signature genes, and to micro-array comprising said set of signature genes.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: December 30, 2014
    Assignee: Agendia B.V.
    Inventors: Paul Roepman, Annuska Maria Glas
  • Means and method for determining tumor cell percentage in a sample
    Patent number: 8658371
    Abstract: The invention provides a method for determining the percentage of tumor cells in a sample of an individual, preferably a breast sample. More specifically, the invention provides one or more genes than can be used to determine the percentage of tumor cells. The invention further provides a set of probes, a set of primers, and uses thereof for detection of said one or more genes.
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: February 25, 2014
    Assignee: Agendia B.V.
    Inventors: Paul Roepman, Annuska Maria Glas